November 22, 2002
The National Institutes of Health has awarded University of Texas Southwest Medical Center-Dallas a $1.95 million grant to study novel treatments for the syndrome, which affects nearly 50 percent of HIV-infected patients who have taken protease inhibitors for more than a year.
"Patients who take protease inhibitors have their HIV infection under control, but they are developing another severe metabolic disorder at the same time," stated Dr. Abhimanyu Garg, professor of internal medicine and the principal investigator of the five-year study. Garg noted that physicians first observed the loss of body fat associated with lipodystrophy in HIV-infected patients in 1997.
Garg and his associates will not treat the metabolic abnormalities with cholesterol-lowering drugs, since these can interfere with HIV medications and also cause serious side effects. The researchers will evaluate three low-risk therapeutic measures on HIV patients who have taken protease inhibitors for at least a year. Participants will eat a high-monounsaturated-fat diet, adhere to a supervised aerobic exercise regimen, and take dietary supplements including fish oils and Benecol, a plant-based margarine.
"We are trying to see how safely we can lower their cholesterol and improve their insulin resistance," Garg continued. "All of the therapies that we will be evaluating in this study have been very beneficial in patients with diabetes and insulin resistance."
The study will also assess the effectiveness of leptin therapy, an investigational treatment that has been shown to greatly reduce triglyceride and glucose levels in patients with inherited and other types of acquired lipodystrophies. Produced by fat cells, leptin is a protein that is nearly absent in patients with generalized lipodystrophies.
Heart Disease Weekly
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.